<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00476788</url>
  </required_header>
  <id_info>
    <org_study_id>X060928006</org_study_id>
    <nct_id>NCT00476788</nct_id>
  </id_info>
  <brief_title>Fast Track CSII Using a Novel Device in Young Children With Newly Diagnosed T1DM</brief_title>
  <official_title>Fast Track Continuous Subcutaneous Insulin Infusion (CSII) in Children With Newly Diagnosed Type 1 Diabetes Mellitus: An Evaluation of a Novel CSII Device in the Immediate Period Following Diagnosis of Type 1 Diabetes (T1DM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates early initiation of continuous subcutaneous insulin infusion (CSII)
      therapy in young children using a novel delivery method in the form of a self-contained,
      lightweight, and disposable insulin pump unit controlled with a wireless handheld device. The
      outcomes of interest are the feasibility and potential metabolic benefits of this approach.
      We anticipate that the initiation of this CSII device in the immediate post-diagnosis period
      in this population will result in good glycemic control and greater parental satisfaction
      when compared to intensive insulin injection therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of type 1 diabetes (T1DM) is on the rise worldwide, especially in children
      younger than six years of age. Glycemic control using multiple daily injection (MDI) therapy
      can be difficult to achieve and maintain in the very young, especially in the immediate
      post-diagnosis period. This study evaluates early initiation of continuous subcutaneous
      insulin infusion (CSII) therapy in young children using a novel delivery method in the form
      of a self-contained, lightweight, and disposable insulin pump unit controlled with a wireless
      handheld device. The outcomes of interest are the feasibility, safety, and potential
      metabolic benefits of this approach. We will recruit 14 pediatric patients, aged one to ten
      years, from a pool of all children newly diagnosed with T1DM admitted to the Children's
      Hospital of Alabama to use the pump.General diabetes education and CSII-specific training
      will take place in a series of outpatient sessions with the PI and study nurse. Pump therapy
      will be initiated within two months of diagnosis providing that all requisite education and
      training has been successfully completed. Data will be collected for both study group and
      control group patients for six months via phone calls and monthly clinic visits. Areas which
      will be evaluated include glycemic control, residual endogenous insulin secretion, frequency
      of severe adverse events, parental distress, insulin needs, and physical growth. While
      initiating CSII in the immediate post-diagnosis period in this population may be initially
      time-intensive, it is anticipated that it will ultimately become time-saving because of the
      greater ease in blood sugar management.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Glycated Hemoglobin (A1c)</measure>
    <time_frame>6.9 months (average)</time_frame>
    <description>Measure of glycemic control (A1c) over preceding 8 weeks. Normal for a patient between ages 1 and 10 years would be 7.0-8.5%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Reported Adverse Events</measure>
    <time_frame>6.9 months (average)</time_frame>
    <description>adverse events are defined as a change from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Omnipod Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be placed on an Omnipod insulin pump</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Omnipod Insulin Management System</intervention_name>
    <description>Initiation of insulin pump therapy within three months of the diagnosis of type 1 diabetes mellitus</description>
    <arm_group_label>Omnipod Device</arm_group_label>
    <other_name>Tubeless insulin pump</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 1 through 10 years of age

          -  Patients present to the Children's Hospital of Alabama with a new diagnosis of type 1
             diabetes

          -  Patients may be admitted to the inpatient unit

          -  OR from the ER

          -  OR or from an outside facility to Children's Hospital

          -  Or seen in our outpatient clinic for the first time having been diagnosed at an
             outside facility

          -  If patients are recruited from the outside facility in our outpatient clinic, the
             diagnosis must have been made within two weeks of the visit. Twenty patients and
             twenty control subjects will be recruited over a six-month period.

        Exclusion Criteria:

          -  Patients with diabetes due to other causes (neonatal diabetes, pancreatitis, cystic
             fibrosis, etc.)

          -  Patients will younger than 2 years of age

          -  Patients older than 8 years of age

          -  Lack any presence of other systemic disease(s), such as neoplastic disease or renal
             failure.

          -  Patients must have adequate parental support and stable home environment (e.g.
             children in foster care or with a history of suspected abuse or neglect would be
             excluded).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elaine C Moreland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2007</study_first_submitted>
  <study_first_submitted_qc>May 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2007</study_first_posted>
  <results_first_submitted>October 12, 2010</results_first_submitted>
  <results_first_submitted_qc>December 20, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 24, 2011</results_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Michael Stalvey, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pediatrics</keyword>
  <keyword>CSII</keyword>
  <keyword>diabetes</keyword>
  <keyword>C-peptide</keyword>
  <keyword>adverse events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Omnipod Device</title>
          <description>Patients will be placed on an Omnipod insulin pump</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Omnipod Device</title>
          <description>Patients will be placed on an Omnipod insulin pump</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.275" spread="2.875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Reported Adverse Events</title>
        <description>adverse events are defined as a change from baseline</description>
        <time_frame>6.9 months (average)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omnipod Device</title>
            <description>Patients will be placed on an Omnipod insulin pump</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Reported Adverse Events</title>
          <description>adverse events are defined as a change from baseline</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Glycated Hemoglobin (A1c)</title>
        <description>Measure of glycemic control (A1c) over preceding 8 weeks. Normal for a patient between ages 1 and 10 years would be 7.0-8.5%.</description>
        <time_frame>6.9 months (average)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omnipod Device</title>
            <description>Patients will be placed on an Omnipod insulin pump</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Glycated Hemoglobin (A1c)</title>
          <description>Measure of glycemic control (A1c) over preceding 8 weeks. Normal for a patient between ages 1 and 10 years would be 7.0-8.5%.</description>
          <units>percentage of glycated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Omnipod Device</title>
          <description>Patients will be placed on an Omnipod insulin pump</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elaine Moreland MD</name_or_title>
      <organization>Greenville Hospital System</organization>
      <phone>8644545661</phone>
      <email>emoreland@ghs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

